10 citations
,
January 2018 in “Dermatology online journal” Genital rejuvenation is becoming popular for improving genital appearance and function in both men and women.
14 citations
,
June 1995 in “The Journal of Clinical Endocrinology and Metabolism”
6 citations
,
September 1997 in “Prostate Cancer and Prostatic Diseases” Finasteride 5 mg effectively reduces urinary symptoms and PSA levels in men with enlarged prostates, with few sexual side effects.
55 citations
,
March 1990 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride may treat baldness but less effective for those with 5α-reductase deficiency.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
15 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” 5α-Reductase inhibitors can negatively affect male sexual function and, in some cases, significantly reduce sperm count, but these effects may be reversible.
3 citations
,
February 2024 in “Wound Repair and Regeneration” Keloids on the penis are rare, often triggered by circumcision, and rarely recur after surgery.
2 citations
,
August 2021 in “The Journal of Urology” The procedure involving seminal vesiculoscopy, TURED, and balloon dilation effectively treated a man's hematospermia and improved his dysorgasmia.
40 citations
,
December 1980 in “The Journal of Dermatologic Surgery and Oncology” An improved scalp reduction technique reduces the need for hair grafts and has minimal complications.
20 citations
,
August 2010 in “The Journal of Urology” Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.
3 citations
,
January 2019 in “PubMed” Platelet-rich plasma may be effective for genital rejuvenation and deserves more research.
2 citations
,
March 2020 in “Baghdad Science Journal” Finasteride effectively reduces DHT and E2 levels, helping with prostate enlargement.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
September 2004 in “Urology” Finasteride may reduce prostate cancer risk.
82 citations
,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
37 citations
,
November 1995 in “Journal of Investigative Dermatology” Topical finasteride and flutamide reduce gland size and enzyme activity, with flutamide being more potent, potentially treating acne, seborrhea, hirsutism, and androgenic alopecia.
7 citations
,
September 1997 in “PubMed” July 2023 in “International Journal of Molecular Sciences” Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.
January 2015 in “Faculty of 1000 Research Ltd” BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.
184 citations
,
January 2000 in “European Urology” Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
March 2009 in “The Journal of Urology” Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.
March 2024 in “Journal of the American Academy of Dermatology” Taking medication for hair loss might cause sexual problems.
May 2022 in “Endocrine Abstracts” Finasteride may cause sexual dysfunction by reducing epinephrine levels.
September 2019 in “Research Square (Research Square)” Micro-CT helps identify suitable areas for surgical procedures based on blood vessel distribution in hypospadias-affected rats.
March 2026 in “Gazzetta Medica Italiana Archivio per le Scienze Mediche” Finasteride effectively treats benign prostatic hyperplasia by reducing prostate size and improving urinary symptoms.
17 citations
,
August 2011 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.
3 citations
,
January 2010 in “Yearbook of Urology” January 2010 in “Yearbook of Urology” 1 citations
,
October 2024 in “JCEM Case Reports” 5α-reductase deficiency can cause ambiguous genitalia and gender dysphoria, treatable with testosterone.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.